Jane Street
TGTX icon

Jane Street’s TG Therapeutics TGTX Stock Holding History

Jane Street’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.1M Buy
995,300
+306,000
+44% +$9.12M ﹤0.01% 1349
2025
Q4 		$20.5M Buy
689,300
+290,800
+73% +$9.5M ﹤0.01% 1604
2025
Q3 		$14.4M Buy
398,500
+152,800
+62% +$5.03M ﹤0.01% 1982
2025
Q2 		$8.84M Sell
245,700
-64,400
-21% -$2.4M ﹤0.01% 2288
2025
Q1 		$12.2M Sell
310,100
-218,100
-41% -$7.34M ﹤0.01% 1756
2024
Q4 		$15.9M Buy
528,200
+334,900
+173% +$9.61M ﹤0.01% 1461
2024
Q3 		$4.52M Buy
193,300
+83,100
+75% +$1.81M ﹤0.01% 3029
2024
Q2 		$1.96M Sell
110,200
-34,900
-24% -$557K ﹤0.01% 4508
2024
Q1 		$2.21M Sell
145,100
-150,900
-51% -$2.4M ﹤0.01% 3952
2023
Q4 		$5.06M Buy
296,000
+95,500
+48% +$1.11M ﹤0.01% 2835
2023
Q3 		$1.68M Sell
200,500
-100,800
-33% -$1.41M ﹤0.01% 4336
2023
Q2 		$7.48M Buy
301,300
+202,900
+206% +$5.24M ﹤0.01% 2233
2023
Q1 		$1.48M Sell
98,400
-126,100
-56% -$1.92M ﹤0.01% 4331
2022
Q4 		$2.66M Buy
224,500
+105,200
+88% +$764K ﹤0.01% 3400
2022
Q3 		$706K Sell
119,300
-8,600
-7% -$56.4K ﹤0.01% 6054
2022
Q2 		$544K Sell
127,900
-51,100
-29% -$319K ﹤0.01% 6588
2022
Q1 		$1.7M Sell
179,000
-42,500
-19% -$492K ﹤0.01% 5064
2021
Q4 		$4.21M Sell
221,500
-18,100
-8% -$470K ﹤0.01% 3120
2021
Q3 		$7.97M Buy
239,600
+56,700
+31% +$1.75M ﹤0.01% 2100
2021
Q2 		$7.09M Buy
182,900
+72,900
+66% +$2.86M ﹤0.01% 2140
2021
Q1 		$5.3M Buy
110,000
+43,100
+64% +$2.07M ﹤0.01% 2325
2020
Q4 		$3.48M Sell
66,900
-13,700
-17% -$463K ﹤0.01% 2604
2020
Q3 		$2.16M Buy
80,600
+38,000
+89% +$874K ﹤0.01% 2917
2020
Q2 		$830K Buy
42,600
+31,000
+267% +$499K ﹤0.01% 4337
2020
Q1 		$114K Buy
+11,600
New +$147K ﹤0.01% 4898
2018
Q4 		– Sell
-33,900
Closed -$190K – 5705
2018
Q3 		$190K Buy
33,900
+12,300
+57% +$141K ﹤0.01% 4707
2018
Q2 		$284K Buy
+21,600
New +$297K ﹤0.01% 4184

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street's TGTX Position: Q1 2026 in Review

Jane Street increased its TG Therapeutics (TGTX) stake by 110% in Q1 2026, buying an estimated $31.9M and bringing the position to 2,041,669 shares worth $67.8M. The position accounts for 0.01% of the portfolio, ranked #863.

Jane Street first reported a position in TGTX in Q2 2013 and has held it in 32 quarters since. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Jane Street held 2,041,669 shares of TG Therapeutics worth $67.8M as of Q1 2026.
  • Jane Street bought 1,071,694 TG Therapeutics shares in Q1 2026, an estimated $31.9M.
  • TG Therapeutics made up 0.01% of Jane Street's portfolio in Q1 2026, its #863 holding.
  • Jane Street first reported a position in TG Therapeutics in Q2 2013 and has held it in 32 quarters since.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.